{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:14Z","timestamp":1787729594689,"version":"build-2784847793"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.mce.2024.112344","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T01:48:18Z","timestamp":1725068898000},"page":"112344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice"],"prefix":"10.1016","volume":"592","author":[{"given":"Jeena","family":"Varghese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Skefos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.mce.2024.112344_bib1","doi-asserted-by":"crossref","first-page":"A880","DOI":"10.1210\/jendso\/bvac150.1823","article-title":"OR29-3 high-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study","volume":"6","author":"Al-ward","year":"2022","journal-title":"J Endocr Soc"},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1541-7786.MCR-20-0992","article-title":"Mastermind like transcriptional coactivator 3 (MAML3) drives neuroendocrine tumor progression","volume":"19","author":"Alzofon","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib3","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.mce.2024.112344_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib5","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1210\/clinem\/dgaa741","article-title":"Genotype-phenotype features of germline variants of the TMEM127 pheochromocytoma susceptibility gene: a 10-year update","volume":"106","author":"Armaiz-Pena","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib7","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib8","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10431","key":"10.1016\/j.mce.2024.112344_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mce.2024.112344_bib10","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2214\/AJR.10.4547","article-title":"Adrenal imaging","volume":"194","author":"Blake","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current concepts in (68)Ga-dotatate imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies","volume":"58","author":"Bodei","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.mayocp.2019.03.030","article-title":"Diagnostic accuracy of computed tomography to exclude pheochromocytoma: a systematic review, meta-analysis, and cost analysis","volume":"94","author":"Buitenwerf","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib14","article-title":"Clinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma","volume":"1879","author":"Casc\u00f3n","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib15","doi-asserted-by":"crossref","DOI":"10.1530\/JME-22-0167","article-title":"Genetic bases of pheochromocytoma and paraganglioma","volume":"70","author":"Cascon","year":"2023","journal-title":"J. Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40618-021-01629-x","article-title":"Management and outcome of metastatic pheochromocytomas\/paragangliomas: a monocentric experience","volume":"45","author":"De","year":"2022","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib21","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr. Rev."},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib23","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib25","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","article-title":"Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses","volume":"108","author":"Fischer","year":"2023","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1210\/jc.2015-3889","article-title":"Pheo-type: a diagnostic gene-expression assay for the classification of pheochromocytoma and paraganglioma","volume":"101","author":"Flynn","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib29","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.mce.2024.112344_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jso.25869","article-title":"Screening guidelines and recommendations for patients at high risk of developing endocrine cancers","volume":"121","author":"Geurts","year":"2020","journal-title":"J. Surg. Oncol."},{"issue":"17","key":"10.1016\/j.mce.2024.112344_bib31","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.mce.2024.112344_bib32","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113070","article-title":"TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation","volume":"42","author":"Guo","year":"2023","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib34","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.mce.2024.112344_bib36","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.mce.2024.112344_bib37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.semnuclmed.2011.03.003","article-title":"Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer","volume":"41","author":"Ilias","year":"2011","journal-title":"Semin. Nucl. Med."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib39","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.mce.2024.112344_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fendo.2018.00277","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.mce.2024.112344_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 Years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.mce.2024.112344_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.mce.2024.112344_bib46","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.mce.2024.112344_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib48","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"108","author":"Jimenez","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, pragmatic approach","volume":"24","author":"Jimenez","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work?","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"108","author":"Jimenez","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib52","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0236","article-title":"Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma","volume":"30","author":"Jimenez","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","article-title":"Genomic landscape of pheochromocytoma and paraganglioma","volume":"4","author":"Jochmanova","year":"2018","journal-title":"Trends Cancer"},{"issue":"22","key":"10.1016\/j.mce.2024.112344_bib55","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.mce.2024.112344_bib56","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2024.112344_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr. Pathol."},{"issue":"17","key":"10.1016\/j.mce.2024.112344_bib58","doi-asserted-by":"crossref","first-page":"24141","DOI":"10.18632\/oncotarget.8234","article-title":"Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma\/paraganglioma","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmedgenet-2019-106324","article-title":"Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis","volume":"57","author":"Lee","year":"2020","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.mce.2024.112344_bib60","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.mce.2024.112344_bib61","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.mce.2024.112344_bib62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.csbj.2020.03.007","article-title":"PreMSIm: an R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer","volume":"18","author":"Li","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041494","article-title":"Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"12","author":"Marretta","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr. Pathol."},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib65","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1210\/clinem\/dgab202","article-title":"Recurrence-free survival analysis in locally advanced pheochromocytoma: first appraisal","volume":"106","author":"Moog","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib66","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib67","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/SLA.0000000000002671","article-title":"Preoperative 18F-fdg PET\/CT in pheochromocytomas and paragangliomas allows for precision surgery","volume":"269","author":"Nockel","year":"2019","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.mce.2024.112344_bib68","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"61","key":"10.1016\/j.mce.2024.112344_bib69","doi-asserted-by":"crossref","first-page":"104046","DOI":"10.18632\/oncotarget.22001","article-title":"Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response","volume":"8","author":"Owen","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib70","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"14","key":"10.1016\/j.mce.2024.112344_bib71","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-17-3406","article-title":"Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma","volume":"24","author":"Pang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mce.2024.112344_bib72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jss.2017.04.011","article-title":"Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma","volume":"215","author":"Parikh","year":"2017","journal-title":"J. Surg. Res."},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib73","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1358332","article-title":"Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior","volume":"6","author":"Pinato","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib74","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.mce.2024.112344_bib75","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib76","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123I-MIBG scintigraphy on clinical decision-making in pheochromocytoma and paraganglioma","volume":"104","author":"Rao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2024.112344_bib77","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/EJE-15-0483","article-title":"Life-threatening events in patients with pheochromocytoma","volume":"173","author":"Riester","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib78","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/archdischild-2023-325419","article-title":"Genotype-phenotype correlations in paediatric and adolescent phaeochromocytoma and paraganglioma: a cross-sectional study","volume":"109","author":"Seabrook","year":"2024","journal-title":"Arch. Dis. Child."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of (68)Ga-dotatate PET\/CT, (18)F-fdg PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib85","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib86","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-15-0456","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"16","key":"10.1016\/j.mce.2024.112344_bib87","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.mce.2024.112344_bib88","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2008-1093","article-title":"Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene","volume":"93","author":"Timmers","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mce.2024.112344_bib89","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib90","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EO-22-0044","article-title":"Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes","volume":"2","author":"Turin","year":"2022","journal-title":"Endocr Oncol"},{"key":"10.1016\/j.mce.2024.112344_bib91","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnae005","article-title":"The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives","author":"Uher","year":"2024","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.mce.2024.112344_bib92","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00268-022-06862-w","article-title":"Genotype-phenotype correlations and clinical outcomes in 155 cases of pheochromocytoma and paraganglioma","volume":"47","author":"Wang","year":"2023","journal-title":"World J. Surg."},{"key":"10.1016\/j.mce.2024.112344_bib93","article-title":"Hypoxia signaling pathway: a central mediator in endocrine tumors","volume":"13","author":"Watts","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.mce.2024.112344_bib94","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.mce.2024.112344_bib95","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score","volume":"33","author":"Wu","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib96","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American association of endocrine surgeons guidelines for adrenalectomy: executive summary","volume":"157","author":"Yip","year":"2022","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.mce.2024.112344_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.mce.2024.112344_bib98","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","article-title":"Metastatic pheochromocytoma: does the size and age matter?","volume":"41","author":"Zelinka","year":"2011","journal-title":"Eur. J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.mce.2024.112344_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165028","article-title":"Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma","volume":"133","author":"Zheng","year":"2023","journal-title":"J. Clin. Invest."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720724002004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720724002004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:39:54Z","timestamp":1726029594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720724002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":99,"alternative-id":["S0303720724002004"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2024.112344","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2024.112344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112344"}}